skip to contents.

TTPP, JETRO's business matching site, provides extensive supports to business people who want to find international business partners for their overseas production, sales assignment, market development and business support services as well as business people who want to start or expand their trade businesses such as export and import transactions.

JAPANESE

Use of kynurenic acid amide derivatives for the treatment of HD

Proposal Number : 1128052       Provide technologies/know-how
Date Date of Registration : Oct 27, 2011
Date of Revision : Oct 27, 2011
Country / AreaCsongrad, Hungary 
Proposal Category 8802 Bio-medicine and therapeutics (vaccines, biological products, bio-diagnostics / pharmaceuticals, gene-diagnostics / therapeutics )
Target Country / Area All Countries / Areas

*Attention: JETRO shall not take any responsibility for the contents provided by users. Please take note of the fact that JETRO leaves the exactness and reliability of the contents to users' judgment.

Detail Description

Use of kynurenic acid amide derivatives for the treatment of HD

<< DESCRIPTION >>
Main advantages:
The therapeutic importance of kynurenic acid analogues is further increased by the fact, that if the broad-spectrum receptory effects of KYNA are retained, they are capable of widespread anti-excitotoxic activity.
KYNA can inhibit N-methyl-D-aspartic (NMDA) acid receptors at the strychnine-insensitive glycine binding sites.
And it can also reduce the release of glutamate by inhibiting the presynaptic alfa-7-nicotinic acetylcholine receptors.
Furthermore several KYNA amides showed selective inhibition of the NR2B subunit containing NMDA receptors, and NMDA receptors containing these subunits have special importance in glutamate-induced excitotoxicity.

Since glycine and polyamine site agents, NR2B subunit specific antagonists and ion channel blockers with lower affinity may come into consideration as NMDA receptor antagonists, as they exert acceptable side-effects, the KYNA amide analogues have a significantly improved side-effect profile compared to other antiglutamatergic agents.
This presents a clear therapeutic advantage for patients.

<< EXAMPLES OF ACTUAL APPLICATIONS >>
Potential areas of use. Treatment of Huntington's disease.

Typical customers
Pharmaceutical Companies

Patent Status
Progress of formalities Pending
Country / Area in Which Registered Hungary
Registered No. HU2011/000062
User Info
Proposals Registered by this Corporation and User    (20 total matches)
Thyroid Hormone Action Indicator Transgenic Mouse

Thyroid Hormone Action Indicator Transgenic Mouse

Provide technologies/know-how

Hungary

Jan 09, 2019 RegistrationJan 09, 2019 Revision

Total Sum of CONTACT Received : 0

Explosive Cladding for the Electrical Industry

Explosive Cladding for the Electrical Industry

Provide technologies/know-how

Hungary

Nov 19, 2018 RegistrationNov 19, 2018 Revision

Total Sum of CONTACT Received : 2

Regenerable Water Filtering for As, I, B, F Contaminated Water

Regenerable Water Filtering for As, I, B, F Contaminated Water

Provide technologies/know-how

Hungary

Nov 15, 2018 RegistrationNov 16, 2018 Revision

Total Sum of CONTACT Received : 6

Innovative Technology to Utilize and Recycle Sewage Sludge

Innovative Technology to Utilize and Recycle Sewage Sludge

Provide technologies/know-how

Hungary

Nov 08, 2018 RegistrationNov 08, 2018 Revision

Total Sum of CONTACT Received : 2

Technology of Manual Propelled Vehicle for Mature Users

Technology of Manual Propelled Vehicle for Mature Users

Provide technologies/know-how

Hungary

Sep 07, 2018 RegistrationSep 07, 2018 Revision

Total Sum of CONTACT Received : 4

More



Previous Page

User Guide

Support Agriculture

Support India

Support Indonesia

RUSSIA x JAPAN Business Matching Support Project

Global Links

News Delivery

You get TTPP new proposals twice a day!

  • E-mail
  • RSS

TTPP news letter Back Numbers